Loading…
Manufactures pharmaceutical-grade mineral compounds (calcium, magnesium, zinc salts) used as excipients and nutraceutical ingredients.
Manufactures pharmaceutical-grade mineral compounds (calcium, magnesium, zinc salts) used as excipients and nutraceutical ingredients.
In one line: A niche pharma-grade mineral excipient maker.
Moat: narrow (process know-how, regulatory licence). Pharma-grade quality certifications for mineral excipients create a technical barrier versus commodity suppliers.
Headquarters: Gujarat, India · Employees: 651
Size Sudeep Pharma (SUDEEPPHRM.NS) is an India Health Care company (Pharmaceuticals: Other) with a market value of $1.41B, the 486th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹1,178 on 6 Nov 2026.
Performance Over six months the shares gained 75.3%, against -9.0% for the median peer and 0.0% for the India market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue grew 26.8% over the last twelve months (peer median +9.6%); the operating margin is 32.9% (peer median 15.4%).
Valuation It trades at 67.7× forward earnings against a peer median of 18.6× (2nd most expensive of 18).
Capital Return on invested capital runs 2.8 points above its cost of capital (13.6% WACC).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹7.10B | ₹6.39B | ₹4.97B | ₹4.55B | ₹4.26B |
| Revenue growth | — | +28% | +9% | +7% | — |
| Gross profit | ₹3.87B | ₹3.17B | ₹2.57B | ₹2.25B | ₹1.44B |
| EBITDA | ₹2.51B | ₹2.31B | ₹1.90B | ₹1.80B | ₹886M |
| Net income | ₹1.88B | ₹1.73B | ₹1.39B | ₹1.33B | ₹623M |
| Free cash flow | n/a | -₹566M | -₹208M | ₹95.9M | -₹33.1M |
| Capital expenditure | n/a | ₹1.18B | ₹642M | ₹525M | ₹472M |
| Total debt | ₹1.89B | ₹1.50B | ₹1.38B | ₹787M | ₹831M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SUDEEPPHRM.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.7% | +0.3% | 10th highest of 21 |
| 6-month return | +75.3% | -9.0% | highest of 21 |
| Distance from 52-week high | -14.5% | -24.2% | 7th highest of 21 |
| Revenue growth (TTM) | +26.8% | +9.6% | 5th highest of 21 |
| Operating margin | 32.9% | 15.4% | 2nd highest of 20 |
| Forward P/E | 67.7× | 18.6× | 2nd most expensive of 18 |
| ROIC minus cost of capital | +2.8 pp | +2.7 pp | 10th highest of 20 |
| EV / EBITDA | 53.6× | 16.1× | 2nd most expensive of 11 |
| Net debt / EBITDA | 0.3× | -0.7× | 4th most indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sudeep Pharma SUDEEPPHRM.NS | India | $1.41B | +75% | +27% | 33% | 67.7× | n/a | n/a |
| Jamieson Wellness JWEL.TO | Canada | $1.35B | +35% | +15% | 15% | 21.2× | 11.0% | +15.3% |
| Cronos CRON.TO | Canada | $1.34B | +45% | +36% | -2% | 15.6× | 2.1% | +26.7% |
| Guilin Sanjin Pharmaceutical 002275.SZ | China | $1.53B | +27% | -3% | 24% | 18.6× | -2.2% | +5.5% |
| Pharma Mar PHM.MC | Spain | $1.30B | -33% | +32% | 19% | 37.7× | 11.4% | -3.9% |
| Bora Pharmaceuticals 6472.TW | Taiwan | $1.55B | -2% | -6% | 15% | 14.2× | 4.5% | +60.2% |
| BioGaia BIOG-B.ST | Sweden | $1.26B | -7% | +13% | 28% | 30.1× | 0.9% | +15.5% |
| Zhejiang Medicine 600216.SS | China | $1.61B | -23% | -6% | 7% | 11.3× | -6.7% | +3.9% |
| Tibet Cheezheng Tibetan Medicine 002287.SZ | China | $1.66B | -15% | -7% | 28% | n/a | -1.1% | +10.4% |
| HBM 2142.HK | Hong Kong | $1.18B | -23% | +55% | 44% | 12.4× | 14.1% | +62.3% |
| Shandong Xinhua Pharmaceutical 0719.HK | Hong Kong | $1.09B | -11% | -1% | 4% | 6.8× | -2.0% | +7.1% |
| Porton Pharma Solutions 300363.SZ | China | $1.92B | +14% | +6% | -2% | n/a | 5.3% | +10.4% |
| Applied Nutrition APN.L | United Kingdom | $1.01B | +42% | +24% | n/a | 24.2× | n/a | n/a |
| New Journey Health Technology Group Co., Ltd.Class A 002219.SZ | China | $999M | -16% | -14% | 8% | 193.0× | n/a | n/a |
| China Meheco 600056.SS | China | $2.00B | -14% | +2% | 3% | n/a | -0.8% | -2.1% |
| Health and Happiness (H&H) International 1112.HK | Hong Kong | $2.05B | +70% | +24% | 16% | 12.6× | -3.0% | +4.4% |
| Granules India GRANULES.NS | India | $2.10B | +8% | +22% | 17% | 24.9× | 23.5% | +10.6% |
| Sihuan Pharmaceutical 0460.HK | Hong Kong | $952M | -35% | +30% | 15% | 9.7× | n/a | n/a |
| China Resources Jiangzhong Pharmaceutical 600750.SS | China | $2.19B | -3% | -10% | 24% | 15.7× | -2.5% | +11.6% |
| TSI 603262.SS | China | $909M | -41% | +3% | 14% | 51.5× | 25.8% | +13.4% |
| PharmaNutra PHN.MI | Italy | $808M | -18% | +18% | 21% | 29.6× | 4.0% | +18.5% |